Item 2.01
Completion of Acquisition or Disposition of Assets.
The Acquisition transaction described above was consummated on October 26, 2018. By acquiring CRX as a wholly-owned subsidiary, Nexien acquired all of its assets, which consist primarily of three U.S. provisional patent applications relating to cannabinoid formulations to treat convulsive disorders, chronic traumatic encephalopathy, and neuropathic pain.
